- Company
- Celltrion wins lawsuit over Mabthera patent
- by Kim, Jin-Gu Mar 2, 2021 06:25am
- Celltrion finally won the patent dispute over Mabthera (Rituximab). Celltrion has been able to completely overcome the patent risk of Mabthera biosimilar Truxima by confirming the victory in the lawsuit that lasted more than five years. On the morning of the 25th, the Supreme Court ruled in an appeal for invalidation of patent registratio
- Company
- Xospata can be prescribed at general hospitals
- by Eo, Yun-Ho Feb 26, 2021 06:26am
- Acute myeloid leukemia treatment Xospata can be prescribed at general hospitals. According to related industries, Xospata (Gilteritinib), a drug for acute myeloid leukemia (AML) of Astellas Korea, has passed the drug committee (DC) of SNUH and SMC, and is also in progress at other major hospitals nationwide. This drug has already been pre
- Company
- Prolia's sales amounted to ₩75.1 billion in 4 years
- by Kim, Jin-Gu Feb 26, 2021 06:26am
- Amgen's Prolia (Denosumab) ranked first in the osteoporosis treatment market. Amgen's Evenity (Romosozumab) is expected to start earning sales this year. Amgen, which has established a lineup leading to Evenity-Prolia in the osteoporosis treatment market, is expected to sustain high sales for some time. Most of the bisphosphonates, which had
- Company
- “Amgen sotorasib as personalized lung cancer treatment”
- by Feb 26, 2021 06:26am
- A Kirsten rat sarcoma virus (KRAS) targeted therapy for treating lung cancer patients is finally getting close to an arm’s reach after 40 years. A KRAS inhibitor sotorasib (codename: AMG 510) in development by Amgen has been authorized by the U.S. Food and Drug Administration (FDA) for a priority review on Feb. 17. A first KRAS treatment co
- Company
- Cancer Committee passes Korean-made new drug Leclaza
- by Eo, Yun-Ho Feb 25, 2021 06:24am
- A Korean-made new drug Leclaza passed the first threshold to receive the National Health Insurance (NHI) listing. A pharmaceutical industry source reported the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee has approved of the NHI reimbursement on Yuhan Corporation’s Leclaza (lazertinib), a third-gen
- Company
- Pfizer's Benefix was approved as a prophylactic treatment
- by Feb 24, 2021 06:02am
- Pfizer Korea (CEO Dong-wook Oh) &8203;&8203;announced on the 22nd that Benefix (Recombinant Blood Coagulation Factor Ⅸ), a hemophilia B treatment, was additionally approved by the MFDS for an indication for routine preventive therapy administered once a week. For those over 12 years of age who are injecting Benefix, a dose of 100 IU/kg
- Company
- Keytruda annual sales top the market for the first time
- by Chon, Seung-Hyun Feb 24, 2021 06:02am
- An immunotherapy Keytruda has topped the South Korean pharmaceutical market for the first time. Its outstanding effect confirmed in treating various cancer types have generated sales profit to dominate the market. Anticancer treatment Tagrisso and immunotherapy Humira surpassed the annual sales of 100 billion won. A pneumococcal pneumonia vaccin
- Company
- Market sales of Saxenda & Qsymia are the highest ever
- by An, Kyung-Jin Feb 23, 2021 06:11am
- Despite COVID-19 incident last year, the domestic obesity treatment market set a new record. the market sales of Qsymia and Saxenda, which is known for injectables to lose weight, expanded to the highest level ever. According to IQVIA on the 23rd, the domestic market for obesity treatments last year was &8361;143 billion. It has achieved the l
- Company
- Gilead on its way to introduce HCV drug Epclusa in Korea
- by Eo, Yun-Ho Feb 23, 2021 06:11am
- Gilead is finally showcasing another pipeline for hepatitis C virus infection. The pharmaceutical industry source reported Gilead Science Korea has submitted an application for the South Korean health authority’s approval on a pan-genotype hepatitis C virus (HCV) infection treatment Epclusa (sofosbuvir/velpatasvir) to be used on an adul
- Company
- Competition between Soliris & Enspryng is predicted in Korea
- by Eo, Yun-Ho Feb 23, 2021 06:11am
- Competition between two expensive drugs is expected in the field of Neuromyelitis Optica Spectrum Disorder Aggravate (NMOSD) According to related industries, Roche's Enspryng (Satralizumab) is in the process of domestic approval, while Handok's Soliris (Eculizumab) recently added an indication for optic neuromyelitis. Soliris has been u
